Syros Pharmaceuticals Toekomstige groei

Future criteriumcontroles 1/6

De winst van Syros Pharmaceuticals zal naar verwachting dalen met 6.6% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 11.3% per jaar. De winst per aandeel zal naar verwachting afnemen met 3.1% per jaar.

Belangrijke informatie

-6.6%

Groei van de winst

-3.1%

Groei van de winst per aandeel

Biotechs winstgroei	37.3%
Inkomstengroei	11.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0LC7 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2	-96	N/A	N/A	3
12/31/2025	5	-83	N/A	N/A	4
12/31/2024	0	-61	N/A	N/A	4
9/30/2024	0	-98	-100	-100	N/A
6/30/2024	4	-132	-111	-111	N/A
3/31/2024	7	-144	-104	-104	N/A
12/31/2023	10	-165	-110	-110	N/A
9/30/2023	9	-105	-123	-122	N/A
6/30/2023	9	-95	-127	-126	N/A
3/31/2023	12	-93	-131	-130	N/A
12/31/2022	15	-95	-124	-123	N/A
9/30/2022	23	-114	-116	-115	N/A
6/30/2022	25	-109	-108	-107	N/A
3/31/2022	24	-97	-109	-108	N/A
12/31/2021	23	-87	-101	-100	N/A
9/30/2021	21	-93	-108	-106	N/A
6/30/2021	20	-86	-95	-94	N/A
3/31/2021	18	-81	-81	-80	N/A
12/31/2020	15	-84	-61	-57	N/A
9/30/2020	10	-74	-50	-38	N/A
6/30/2020	7	-74	-48	-34	N/A
3/31/2020	4	-76	-54	-40	N/A
12/31/2019	2	-75	-73	-60	N/A
9/30/2019	2	-74	-68	-63	N/A
6/30/2019	2	-70	-65	-62	N/A
3/31/2019	2	-64	-60	-58	N/A
12/31/2018	2	-62	-42	-40	N/A
9/30/2018	1	-60	-38	-37	N/A
6/30/2018	1	-58	N/A	-37	N/A
3/31/2018	0	-57	N/A	-34	N/A
12/31/2017	1	-54	N/A	-45	N/A
9/30/2017	1	-50	N/A	-44	N/A
6/30/2017	1	-50	N/A	-43	N/A
3/31/2017	1	-51	N/A	-43	N/A
12/31/2016	0	-51	N/A	-41	N/A
9/30/2016	N/A	-52	N/A	-39	N/A
6/30/2016	N/A	-48	N/A	-35	N/A
3/31/2016	0	-41	N/A	-30	N/A
12/31/2015	0	-35	N/A	-23	N/A
9/30/2015	0	-28	N/A	-18	N/A
12/31/2014	N/A	-16	N/A	-12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 0LC7 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 0LC7 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 0LC7 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 0LC7 ( 11.3% per jaar) zal naar verwachting sneller groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van 0LC7 ( 11.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 0LC7 naar verwachting over 3 jaar hoog zal zijn

Syros Pharmaceuticals Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Recent updates

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought US$161k worth of stock

New minor risk - Market cap size

New minor risk - Profitability

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Insufficient new directors

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Insufficient new directors

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Insufficient new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Insufficient new directors

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations

Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten